FierceBiotech Radio on Gilead's maxed-out revenue and BioMarin's FDA struggles

In an episode free of Valeant Pharmaceuticals ($VRX) and Martin Shkreli, FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss a Senate investigation into Gilead Sciences' ($GILD) pricing of the hepatitis C drug Sovaldi, BioMarin's ($BMRN) efforts to win approval for a rare disease treatment and GlaxoSmithKline's latest woes in China.

Download the episode on iTunes or Stitcher, or listen below--and be sure to subscribe. Let us know what you think by dropping a line to [email protected]

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.